Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer

Fujimoto, Naohiro; Shiota, Masaki; Tomisaki, Ikko; Minato, Akinori

doi:10.1016/j.clgc.2017.01.006

Cited by 17 publications

(25 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, investigation into associations between genetic factors and outcomes after hormone therapy is required. Additionally, several germline polymorphisms are reportedly associated with outcomes of androgen‐deprivation therapy, which might also partially affect outcomes of familial prostate cancer …”

Section: Discussionmentioning

confidence: 99%

“…Additionally, several germline polymorphisms are reportedly associated with outcomes of androgen-deprivation therapy, which might also partially affect outcomes of familial prostate cancer. 23 The present study was limited by its retrospective design and incomplete assessment of family history, which depended on self-reporting by patients and queries by physicians, which is affected by recall bias, adoption, education and the number of male family members. 24 We found a much lower frequency of family history than reported for Western countries; this discrepancy might be attributable to differences in the prevalence of prostate cancer in Asian and Western populations, 25 with the prevalence of familial prostate cancer in Japan being just 3.6-6.5%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Family history in primary hormone therapy for prostate cancer: Analysis from a community‐based multi‐institutional Japan‐wide database

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objectives To determine the association between hormone therapy and outcomes in a cohort of prostate cancer patients with a family history of prostate cancer. Methods Data of patients with prostate cancer who had received hormone therapy were extracted from a nationwide community‐based database established by the Japan Study Group for Prostate Cancer. Family history of prostate cancer was available for 13 346 of these patients, who thus comprised the study cohort. Prognostic variables, including progression‐free survival, cancer‐specific survival and overall survival, were compared between men with familial and men with sporadic prostate cancer. Results A positive family history was identified in 220 patients (1.6%). Patients with a positive family history were younger than those without; however, other clinicopathological characteristics and prognoses were comparable. In subgroup analysis, family history was identified as a possible favorable prognostic factor for overall survival among patients with a prostate‐specific antigen level at diagnosis <100 ng/mL and those with low or intermediate Japan Cancer of the Prostate Risk Assessment. Conclusions Our findings show that familial prostate cancer has an early‐onset feature or is diagnosed earlier than sporadic prostate cancer. However, the prognosis of individuals with familial prostate cancer undergoing hormone therapy is comparable to those with sporadic prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Family history in primary hormone therapy for prostate cancer: Analysis from a community‐based multi‐institutional Japan‐wide database

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, little is known of a genetic stratification of the disease or even genetic responsiveness to radical prostatectomy, radiotherapy or hormonal therapies including ADT and second-generation hormonal agents (such as abiraterone and enzalutamide) [ 20 ]. PCa is a hormone-dependent cancer; the androgen receptor ( AR ) axis plays a pivotal role in both disease development and progression [ 21 ]; for this reason we focused on PCa sex hormones related genes, to perform a retrospective study for the relation among AR , CYP17A1 , LHCGR and ESR polymorphisms with PCa predisposition and severity.…”

Section: Discussionmentioning

confidence: 99%

Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness

et al. 2017

View full text Add to dashboard Cite

Novel biomarkers for prostate cancer (PCa) diagnosis and prognosis are necessary to improve the accuracy of current ones employed in clinic. We performed a retrospective study between the association of several polymorphisms in the main genes involved in the synthesis and metabolism of sex hormones and PCa risk and aggressiveness. A total of 311 Caucasian men (155 controls and 156 patients) were genotyped for 9 SNPs in AR, CYP17A1, LHCGR, ESR1 and ESR2 genes. Diagnostic PSA serum levels, Gleason score, tumor stage, D´Amico risk and data of clinical progression were obtained for patients at the moment of the diagnosis and after 54 months of follow-up. Chi-squared test were used for comparisons between clinical variables groups, logistic regression for clinical variables associations between SNPs; and Kaplan–Meier for the association between SNPs and time to biochemical progression. We found 5 variants (CYP17A1) rs743572, rs6162, rs6163; (LHCGR) rs2293275 and (ESR2) rs1256049 that were statistically significant according to clinical variables (PSA, D´Amico risk and T stage) on a case-case analysis. Moreover, the presence of and alleles in rs743572 and rs6162 respectively, increase the risk of higher PSA levels (>10 ng/μl). With respect to D´Amico risk rs743572 (), rs6162 () and rs6163 () were associated with an increased risk; and last, and genotypes for rs6163 were associated with a shorter biochemical recurrence free survival (BRFS) in patients with radical prostatectomy. In multigene analysis, several variants in SNPs rs2293275, rs6152, rs1062577, rs6162, rs6163, rs1256049 and rs1004467 were described to be associated with a more aggressiveness in patients. However, none of the selected SNPs show significant values between patients and controls. In conclusion, this study identified inherited variants in genes CYP17A1, LHCGR and ESR2 related to more aggressiveness and/or a poor progression of the disease. According to this study, new promise PCa biomarkers for clinical management could be included in these previous SNPs.

show abstract

“…As a result, only the GSH S‐transferase mu 3 ( GSTM3 ) rs7483 single nucleotide polymorphism was associated with significant progression risk (AG/GG vs. AA; HR [95% CI], 0.45 [0.25–0.79], P = 0.0047). The levels of intracellular ROS and GSTM3 expression were up‐regulated in both castration‐resistant and enzalutamide‐resistant cells (Fujimoto, Shiota, Tomisaki, & Minato, 2017; Shiota et al, 2017).…”

Section: Mechanisms Of Enzaluide Resistance In Castration‐resistant Pmentioning

confidence: 99%

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Wang

Chen

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

Prostate cancer is the second most common malignancy in men and androgen deprivation therapy is the first-line therapy. However, most cases will eventually develop castration-resistant prostate cancer after androgen deprivation therapy treatment. Enzalutamide is a second-generation androgen receptor antagonist approved by the Food and Drug Administration to treat patients with castrationresistant prostate cancer. Unfortunately, patients receiving enzalutamide treatment will ultimately develop resistance via various complicated mechanisms. This review examines the emerging information on these resistance mechanisms, including androgen receptor-related signalling pathways, glucocorticoid receptor-related pathways and metabolic effects. Notably, lineage plasticity and phenotype switching, gene polymorphisms and the relationship between microRNAs and drug resistance are addressed. Furthermore, potential therapeutic strategies for enzalutamideresistant castration-resistant prostate cancer treatment are suggested, which can help discover more effective and specific regimens to overcome enzalutamide resistance.

show abstract

Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer

Cited by 17 publications

References 47 publications

Family history in primary hormone therapy for prostate cancer: Analysis from a community‐based multi‐institutional Japan‐wide database

Family history in primary hormone therapy for prostate cancer: Analysis from a community‐based multi‐institutional Japan‐wide database

Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Contact Info

Product

Resources

About